Journal of PeriAnesthesia Nursing
Volume 25, Issue 2 , Pages 94-103 , April 2010

Contrast Media Use in the Operating Room

  • Peggy Bickham, PharmD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Dr Peggy Bickham, University of Illinois Medical Center, Hospital Pharmacy Services (MC883), 1740 West Taylor Street, Room C300, Chicago, IL 60612-7239
    • ,
  • Julie Golembiewski, PharmD

References 

  1. Federal Food, Drug, and Cosmetic Act, Sec. 201. (21 U.S.C. 321), Chapter II (Definitions). July 13, 2009. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChaptersIandIIShortTitleandDefinitions/ucm086297. Accessed November 30, 2009.
  2. American College of Radiology; ACR Committee on Drugs and Contrast Media. Manual on Contrast Media, Version 6.0. Reston, VA: American College of Radiology; 2008;
  3. GE Healthcare. Omnipaque (iohexol) injection (product insert). Princeton, NJ: GE Healthcare. Revised September 2007.
  4. Brown JJ. Implementing medication management standards for contrast media. Contrast agents—an overview. Presented at the 41st ASHP Mid-Year Clinical Meeting, Anaheim, California, December 3, 2006. Available at: http://www.ashp.org/DocLibrary/Policy/ContrastMedia/Contrast-Media.pdf. Accessed February 19, 2010.
  5. Institute for Safe Medication Practices. Intrathecal Injection of Ionic Contrast Media May Be Fatal. Medication Safety Alert, November 27, 2003. Available at: http://www.ismp.org/Newsletters/acutecare/articles/20031127.asp?ptr=y. Accessed November 13, 2007.
  6. Bourin M, Joliet P, Ballereau F. An overview of the clinical pharmacokinetics of x-ray contrast media. Clin Pharmacokinet. 1997;32:190–193
  7. Deray G. Dialysis and iodinated contrast media. Kidney Int. 2006;69:S25–S29
  8. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354:379–386
  9. Phillips BD, Hennessey JV. Iodinated contrast prior to evaluation for thyrotoxicosis. J Hosp Med. 2004;4:285–288
  10. European Society of Urogenital Radiology. ESUR Guidelines on Contrast Media, Version 6, 2007. Available at: http://www.esur.org/ESUR_Guidelines.6.0.html. Accessed November 30, 2009.
  11. GE Healthcare. Visipaque (iodixanol) injection (product insert). Princeton, NJ: GE Healthcare. Revised April 2008.
  12. Thomsen H. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR. 2003;181:1466–1471
  13. Wong GTC, Irwin MG. Contrast-induced nephropathy. Br J Anaesth. 2007;99:474–483
  14. Goldenberg I, Shlomi M. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventative strategies. Can Med Assoc J. 2005;172:1461–1471
  15. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Available at: http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm. Accessed March 12, 2008.
  16. Navaneethan SD, Singh S, Appasamy S, et al. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: A systematic review and meta-analysis. Am J Kidney Dis. 2009;53:617–627
  17. Briguori C, Airoldi F, D'Andrea D, et al. Renal insufficiency following contrast media administration trial (REMEDIAL): A randomized comparison of 3 preventative strategies. Circulation. 2007;115:1211–1217
  18. Solomon R, Deray G (Consensus panel for CIN). How to prevent contrast-induced nephropathy and manage risk patients: Practical recommendations. Kidney Int. 2006;69:S51-S53.
  19. Solomon RJ, et al. Cardiac angiography in renally impaired patients (CARE) study. Circulation. 2007;115:3189–3196
  20. Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: A double-blind comparison of iodixanol and iopamidol (The IMPACT Study). Invest Radiol. 2006;41:815–821
  21. Solomon R, Briguori C, Bettman M. Selection of contrast media. Kidney Int. 2006;69:S39–S45
  22. National Kidney Foundation . Guideline 2: Coronary artery disease. Am J Kidney Diseases. 2005;45(Suppl 3):S18–S20
  23. Anderson JL, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007;50:e112
  24. McCullough PA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692–699
  25. Jo SH, et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography (RECOVER) study. J Am Coll Cardiol. 2006;48:924–930
  26. Solomon RJ, Mehran R, et al. Contrast-induced nephropathy and long-term adverse events: Cause and effect?. Clin J Am Soc Nephrol. 2009;4:1162–1169
  27. Sharma SK. Iodinated contrast media and contrast-induced nephropathy: Is there a preferred cost-effective agent?. J Invasive Cardiol. 2008;20:245–248
  28. Coakley FV, Panicek DM. Iodine allergy: An oyster without a pearl?. AJR. 1997;169:951–952
  29. Brockow K. Contrast media hypersensitivity—scope of the problem. Toxicology. 2005;189–192
  30. Delaney A, Carter A, Fisher M. The prevention of anaphylactoid reactions to iodinated radiological contrast media: A systematic review. BMC Med Imag. 2006;6:2
  31. Spinosa DJ, Kaufmann JA, Hartwell GD. Gadolinium chelates in angiography and interventional radiology: A useful alternative to iodinated contrast for angiography. Radiology. 2002;223:319–325
  32. Rieger J, Sitter T, Toepfer M, et al. Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant. 2002;17:824–828
  33. Nyman U, Elmstahl B, Leander P, et al. Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia?. Radiology. 2002;223:311–318
  34. Briguori C, Colombo A, Airoldi F, et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheterization and Cardiovascular Interventions. 2006;67:175–180
  35. Grobner T. Gadolinium—A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
  36. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology. 2007;243:148–157
  37. Broome DR, Girguid MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. AJR. 2007;188:586–592
  38. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–2362

PII: S1089-9472(10)00047-X

doi: 10.1016/j.jopan.2010.01.013

Journal of PeriAnesthesia Nursing
Volume 25, Issue 2 , Pages 94-103 , April 2010

Article Tools